Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Alternext  >  Neovacs    ALNEV   FR0004032746

NEOVACS (ALNEV)
Mes dernières consult.
Most popular
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Alternext
08/17/2017 08/18/2017 08/21/2017 08/22/2017 08/23/2017 Date
0.74(c) 0.74(c) 0.72(c) 0.72(c) 0.71(c) Last
331 041 146 284 271 313 224 300 238 438 Volume
0.00% 0.00% -2.70% 0.00% -1.39% Change
More quotes
Financials (€)
Sales 2017 4,60 M
EBIT 2017 -2,97 M
Net income 2017 -
Debt 2017 -
Yield 2017 -
Sales 2018 14,0 M
EBIT 2018 -1,71 M
Net income 2018 -
Debt 2018 -
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales2017 9,64x
Capi. / Sales2018 3,17x
Capitalization 44,4 M
More Financials
Company
Neovacs SA is a biotechnology company which engages in the development of active immunotherapies for treating auto-immune, inflammatory and cancerous diseases.It focuses on the development of Tumor Necrosis Factor-Kinoid for treating Crohn's disease and rheumatoid polyarthritis and... 
More about the company
Latest news on NEOVACS
08/04 NEOVACS : Announces the closing of a €6.0 million private placement with u.s. bi..
08/04 NEOVACS : Announces the closing of a €6.0 million private placement with u.s. bi..
07/31 NEOVACS : Successfully raises €6.0 million in private...
07/31 NEOVACS : Successfully raises €6.0 million in private placement with u.s. biotec..
07/31 NEOVACS : Successfully raises €6.0 million in private placement with u.s. biotec..
07/27 NEOVACS : regulated- information_liquidity contract juin 2017
07/26 NEOVACS : regulated-information-reglementee30062017
07/19 NEOVACS : Announces FDA Acceptance of a New IND to Expand in U.S....
07/19 NEOVACS : Announces FDA Acceptance of a New IND to Expand in U.S. IFNalpha Kinoi..
07/14 NEOVACS : Phase 2 Trial of Neovacs Lupus Interferon Immunotherapy Receives Anoth..
More news
Sector news : Biotechnology & Medical Research - NEC
08/17 FDA expands use of AstraZeneca/Merck ovarian cancer drug
08/15 Three CEOs resign from Trump council over Charlottesville
08/14DJHot Stocks to Watch in the U.S. and Canada
08/11DJGILEAD SCIENCES : England's NHS Turns to Clinical Trial to Make Cheaper HIV Drug..
08/11DJGILEAD SCIENCES : England's NHS Turns to Clinical Trial to Make Cheaper HIV Drug..
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
08/04NEOVACS ANNOUNCES THE CLOSING OF A €6.0 MILLION PRIVATE PLACEMENT WITH U.S. B.. 
08/04NEOVACS ANNOUNCES THE CLOSING OF A €6.0 MILLION PRIVATE PLACEMENT WITH U.S. B.. 
08/04Neovacs : ANNOUNCES THE CLOSING OF A €6.0 MILLION PRIVATE PLACEMENT WITH U.S... 
07/31NEOVACS : SUCCESSFULLY RAISES €6.0 MILLION IN PRIVATE...  
07/26neovacs : regulated-information-reglementee30062017  
More tweets
Qtime:16
Chart NEOVACS
Duration : Period :
Neovacs Technical Analysis Chart | ALNEV | FR0004032746 | 4-Traders
Technical analysis trends NEOVACS
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 3,07 €
Spread / Average Target 326%
EPS Revisions
Managers
NameTitle
Miguel Sieler Chief Executive Officer & Director
Jean-Jacques Bertrand Chairman
Baptiste Pourtout Head-Finance
Géraldine Grouard-Vogel Chief Scientific Officer
Thérèse Croughs Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
NEOVACS-11.11%52
INCYTE CORPORATION20.56%25 479
QUINTILES IMS HOLDINGS INC22.39%20 512
LONZA GROUP40.29%18 025
CELLTRION, INC.--.--%12 698
ALNYLAM PHARMACEUTICALS, INC.117.47%7 871